New combo pill aims to boost cystic fibrosis treatment
NCT ID NCT07108153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug called SION-719 to the standard CF medication Trikafta is safe and helps people with cystic fibrosis who have two copies of the F508del mutation. Sixteen participants will receive either SION-719 or a placebo alongside their usual Trikafta. The main focus is on safety, but researchers will also measure changes in sweat chloride, a key marker of CFTR function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SION-719 (added to Trikafta)
What this could lead to
If successful, this could point toward a more effective treatment for cystic fibrosis by improving lung function and reducing symptoms when combined with existing therapy.
What could go wrong
This is a small, early-phase study with only 16 participants, so results may not apply to everyone. The main goal is safety, and it's unclear if the added drug will provide meaningful benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University
New York, New York, 10032, United States
-
Gold Coast University Hospital
Southport, Queensland, 4215, Australia
-
Johns Hopkins
Baltimore, Maryland, 21205, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Monash University
Melbourne, Victoria, 3004, Australia
-
National Jewish Health
Denver, Colorado, 80206, United States
-
New York Medical College
Hawthorne, New York, 10532, United States
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
University Hospital of Cleveland
Cleveland, Ohio, 44106, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Washington University
St Louis, Missouri, 63110, United States